Business
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial
About this update from Editas Medicine, Inc.
[{"type":"text","content":"Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT Company to provide a clinical update on the Phase 1/2 BRILLIANCE trial for EDIT-101 this month CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the third quarter of 2022. “I am pleased with our continued progress, and I look forward to providing clinical updates on EDIT-101 and EDIT-301 in the next two months,” commented Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. “We are focused on positioning and advancing our portfolio towards our goal of bringing differentiated medicines to people living with serious diseases.” Recent Achievements and Outlook Ex Vivo Medicines EDIT-301 for Sickle Cell DiseaseSecond patient dosed in RUBY trial; on track to provide initial clinical data by year-end Editas Medicine has dosed the second patient and continues to enroll study participants in the Phase 1/2 RUBY trial for the treatment of severe sickle cell disease.The Company remains on track to present initial preliminary clinical data for the RUBY study by year-end. EDIT-301 for Transfusion-Dependent Beta Thalassemia (TDT)First patient apheresis and editing completed The Company has completed editing CD34+ hematopoietic stem cells for the first enrolled patient in the Phase 1/2 EDITHAL trial for TDT and is scheduling dosing. In Vivo Medicines EDIT-101 for Leber Congenital Amaurosis 10 (LCA10)BRILLIANCE clinical update to be provided this month The Company remains on track to provide an update on the Phase 1/2 BRILLIANCE clinical trial this month, including safety and efficacy data. EDIT-103 for Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)Presented preclinical data at ESGCT In October, Editas Medicine presented preclinical data during an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting.The data demonstrated nearly 100% gene editing knockout of the endogenous RHO gene, with the replacement RHO gene producing over 30...